Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.5, and our video podcast, CANCER BUZZ TV.

Industry News Archive

Positive Phase 3 Cemiplimab Results in Advanced Cervical Cancer

On Wednesday, May 12, Regeneron Pharmaceuticals, Inc. and Sanofi announced the presentation of positive results from the Phase 3 trial investigating the PD-1 inhibitor cemiplimab (Libtayo®) in patients with recurrent or metastatic cervical cancer who had previously progressed on chemotherapy.

The data were shared as part of a European Society for Medical Oncology Virtual Plenary and add to previously reported data showing an improvement in overall survival (OS) with Libtayo compared to chemotherapy. The data will form the basis of regulatory submissions in 2021.

Read the press release.

Posted on 5/12/2021

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us